drugset / Trial / NCT05756595

A Clinical Study of Freshly Manufactured 35kDa Hyaluronan Fragment in the Treatment of Pain

NCT05756595

NaSingle-groupOpen-labelTreatment

Summary

Local used high molecular weight Hyaluronan (HA) with high viscosity has a variety of receptors in the human body, including CD44, LYVE-1, RHAMM, HARE, Siglec-9, TLR2, CEMIP and TMEM2. Intra-articular local injection of HA has a certain degree of analgesic effect. Local injection of HA into the nerve trunk directed by ultrasound was used for the treatment of neuropathic pain. It was reported that the analgesic effect of HA is regulated by TRPV1 ion channels. This study hypothesizes that hyaluronidase cleaves HA to generate low molecular weight HA fragments HA35 with good tissue permeability, which may bind to a variety of HA receptors on the cell surface within the tissues and produce a broad-spectrum analgesic effect. In this study, 35kDa Hyaluronan fragment HA35 was prepared by mixing hyaluronidase PH20 injection and high molecular weight Hyaluronan (HA) injection at room temperature for 20 minutes. In this study, hyaluronidase injection and Hyaluronan injection were off-label used to conduct an investigator-initiated study (IIT or IIS) for the treatment of herpes zoster and shoulder, neck, back and temporal pain.

Timeline

Start
2020-07-06
Primary completion
2022-12-29
Completion
2023-02-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Hyaluronate Other / unclassified Other
Background Berahyaluronidase alfa Protein / enzyme biologic 2000 iu Other
Background H20174089 Unknown 100 mg Other

Indications